RU2019111768A3 - - Google Patents

Download PDF

Info

Publication number
RU2019111768A3
RU2019111768A3 RU2019111768A RU2019111768A RU2019111768A3 RU 2019111768 A3 RU2019111768 A3 RU 2019111768A3 RU 2019111768 A RU2019111768 A RU 2019111768A RU 2019111768 A RU2019111768 A RU 2019111768A RU 2019111768 A3 RU2019111768 A3 RU 2019111768A3
Authority
RU
Russia
Application number
RU2019111768A
Other languages
Russian (ru)
Other versions
RU2019111768A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019111768A publication Critical patent/RU2019111768A/ru
Publication of RU2019111768A3 publication Critical patent/RU2019111768A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2019111768A 2016-09-23 2017-09-22 Противораковые агенты и их получение RU2019111768A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662398783P 2016-09-23 2016-09-23
US62/398,783 2016-09-23
PCT/US2017/052967 WO2018057897A1 (en) 2016-09-23 2017-09-22 Anti-cancer agents and preparation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2023103324A Division RU2023103324A (ru) 2016-09-23 2017-09-22 Противораковые агенты и их получение

Publications (2)

Publication Number Publication Date
RU2019111768A RU2019111768A (ru) 2020-10-23
RU2019111768A3 true RU2019111768A3 (cg-RX-API-DMAC7.html) 2020-11-24

Family

ID=61690726

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019111768A RU2019111768A (ru) 2016-09-23 2017-09-22 Противораковые агенты и их получение

Country Status (14)

Country Link
US (2) US10858371B2 (cg-RX-API-DMAC7.html)
EP (1) EP3515492B1 (cg-RX-API-DMAC7.html)
JP (1) JP7111722B2 (cg-RX-API-DMAC7.html)
KR (1) KR102646702B1 (cg-RX-API-DMAC7.html)
CN (1) CN109862916A (cg-RX-API-DMAC7.html)
AU (1) AU2017331260B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019005885A2 (cg-RX-API-DMAC7.html)
CA (1) CA3037883A1 (cg-RX-API-DMAC7.html)
DK (1) DK3515492T3 (cg-RX-API-DMAC7.html)
IL (1) IL265521B2 (cg-RX-API-DMAC7.html)
MA (1) MA46291A (cg-RX-API-DMAC7.html)
MX (1) MX394670B (cg-RX-API-DMAC7.html)
RU (1) RU2019111768A (cg-RX-API-DMAC7.html)
WO (1) WO2018057897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017331260B2 (en) 2016-09-23 2024-11-07 Purdue Research Foundation Anti-cancer agents and preparation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
US7825267B2 (en) * 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
WO2009031999A1 (en) * 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fr901464 and analogs with antitumor activity and method for their preparation
CN101417934B (zh) * 2007-10-24 2012-04-18 国鼎生物科技股份有限公司 分离自牛樟芝萃取物的化合物
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
WO2009155606A1 (en) * 2008-06-21 2009-12-23 St. Jude Children's Research Hospital Anticancer compounds and methods of making and using same
US20150025017A1 (en) * 2012-02-28 2015-01-22 Fred Hutchinson Cancer Research Center Compositions and methods for treating cancer
MX340090B (es) * 2012-11-05 2016-06-23 Pfizer Analogos de spliceostatina.
WO2014100367A1 (en) * 2012-12-21 2014-06-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthesis of fr901464 and analogs with antitumor activity
US20140274979A1 (en) * 2013-03-13 2014-09-18 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
CN105611930B (zh) 2013-07-15 2021-03-02 亥姆霍兹慕尼黑中心-德国环境与健康研究中心(股份有限公司) 作为非凋亡调控性细胞死亡抑制剂的螺环喹喔啉衍生物
KR102092569B1 (ko) * 2013-09-17 2020-03-25 엘지디스플레이 주식회사 터치 스크린 일체형 디스플레이 장치와 이의 구동 방법
US10000505B2 (en) 2013-11-19 2018-06-19 Purdue Research Foundation Anti-cancer agents and preparation thereof
EP3468976A4 (en) * 2016-06-08 2019-11-27 William Marsh Rice University DERIVATIVES OF THAILANSTATIN A, METHOD FOR THE TREATMENT AND METHOD FOR SYNTHESIS THEREOF
AU2017331260B2 (en) 2016-09-23 2024-11-07 Purdue Research Foundation Anti-cancer agents and preparation thereof

Also Published As

Publication number Publication date
KR102646702B1 (ko) 2024-03-11
RU2019111768A (ru) 2020-10-23
IL265521A (en) 2019-05-30
IL265521B1 (en) 2024-05-01
WO2018057897A1 (en) 2018-03-29
IL265521B2 (en) 2024-09-01
US20190218228A1 (en) 2019-07-18
MA46291A (fr) 2019-07-31
US20210395265A1 (en) 2021-12-23
AU2017331260A1 (en) 2019-05-16
EP3515492A1 (en) 2019-07-31
CN109862916A (zh) 2019-06-07
JP2019529563A (ja) 2019-10-17
MX2019003368A (es) 2019-09-16
AU2017331260B2 (en) 2024-11-07
BR112019005885A2 (pt) 2020-06-02
CA3037883A1 (en) 2018-03-29
EP3515492B1 (en) 2023-07-26
KR20190077340A (ko) 2019-07-03
US11851441B2 (en) 2023-12-26
MX394670B (es) 2025-03-11
US10858371B2 (en) 2020-12-08
EP3515492A4 (en) 2020-04-08
DK3515492T3 (da) 2023-08-28
JP7111722B2 (ja) 2022-08-02

Similar Documents

Publication Publication Date Title
BR112018068177A2 (cg-RX-API-DMAC7.html)
BR112019002665A2 (cg-RX-API-DMAC7.html)
BR112018004986A2 (cg-RX-API-DMAC7.html)
BR112019001429A2 (cg-RX-API-DMAC7.html)
BR212018070320U2 (cg-RX-API-DMAC7.html)
BR112019011044B1 (pt) Compostos de pirazol substituído, seu uso, e composição farmacêutica
BR112019008501B1 (pt) Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador
BR112019003116B1 (pt) Configuração de símbolo de rajada comum de uplink
BR112019001236B1 (pt) Método para executar uma função suplementar para uma consulta de linguagem natural apresentada a um aplicativo de orientação de mídia interativa
BR112019000061B1 (pt) Comutação e modulação de splicing de pré-mrna compreendendo porções de arcabouço bicíclico, com características melhoradas para o tratamento de distúrbios genéticos
BR112018076493B1 (pt) Sistemas e métodos para detecção de posição de feixe de luz
BR112018073794B1 (pt) Partícula, método de geração da partícula, vacina ou composição farmacêutica
BR112018072681B1 (pt) Anticorpos anti-il-1r3 humanizados, fragmento ou derivado do mesmo, seu uso e composição farmacêutica
BR122026002520A2 (pt) Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno
BR112019006736A2 (cg-RX-API-DMAC7.html)
BR112019003108A2 (cg-RX-API-DMAC7.html)
CN303638998S (zh) 瓶子
CN303627104S (zh) 蛋形管喇叭头(衡器用)
CN303649097S (zh) 壁装式淋浴器
CN303621735S (zh) 啤酒易拉罐(经典1903)
CN303656016S (zh) 胸牌(lx93)
CN303641849S (zh) 带图形用户界面的电外科高频发生器
CN303648055S (zh) 嵌入式光纤换位导线
CN303607221S (zh) 手提充电宝led灯
CN303548435S (zh) 手摇晾衣架滑轮盖